Abstract:The baseline platelet count and on‐treatment hepatitis B surface antigen glycan isomer/hepatitis B surface antigen (HBsAgGi/HBsAg) ratio were useful predictors of hepatocellular carcinoma (HCC) development during nucleoside/nucleotide analog (NA) therapy. In addition, it suggests that a combination of on‐treatment HBsAgGi and HBsAg may lead to an increase in the accuracy of predictions of the development of HCC during NA therapy compared with HBsAg alone. Aim A recombinant monoclonal antibody against the hepatitis B surface antigen glycan isomer (HBsAgGi) was newly developed using the O‐glycosylated PreS2 peptide in M‐HBsAg of hepatitis B virus (HBV) genotype C. However, the association between HBsAgGi and the development of hepatocellular carcinoma (HCC) during nucleoside/nucleotide analog (NA) therapy remains unknown. Methods A total of 112 HBV genotype C‐infected patients who were treated with NA were included in this study. We assessed the association between HBV markers, including HBsAgGi and other conventional markers, and the development of HCC during NA therapy. Results Ten patients developed HCC during the follow‐up period. Of the HBV markers, HBsAg (≤3.53 log IU/mL; p = 0.047), HBsAgGi/HBsAg ratio (≥1.10; p = 0.035), and HBV DNA (≤6.3 log copies/mL; p = 0.012) at baseline and HBsAg (≤3.19 log IU/mL; p = 0.033) and HBsAgGi/HBsAg ratio (≥1.09; p = 0.003) at 48 weeks after NA therapy were significantly associated with the development of HCC according to the log rank test. In contrast, no significant association was observed between HBsAgGi and the development of HCC. Multivariate analysis revealed that a platelet count at baseline ≤88 × 103/mm3 (p = 0.026; hazard ratio [HR], 10.577) and an HBsAgGi/HBsAg ratio at 48 weeks after NA therapy ≥1.09 (p = 0.040; HR, 10.099) were independently and significantly associated with the development of HCC. Conclusions Our findings suggest that a combination of on‐treatment HBsAgGi and HBsAg predicts the development of HCC during NA therapy.

Kinetics of serum O‐glycosylated M‐hepatitis B surface antigen with hepatocellular carcinoma history and nucleos(t)ide analogue therapy in hepatitis B patients

HBcrAg, Pg RNA and HBsAg Dynamically Supervise the Seroconversion of HBsAg with Anti-Viral Therapy "loss of HBsAg" Maybe Not a Good End-Point of Anti-Viral Therapy

HBcrAg and Pg RNA and the Therapeutic Effect in HBeAg‐positive Patients Receiving Anti‐viral Therapy, Baseline Serum HBV‐RNA is a Powerful Predictor of Response

Hepatitis B surface antigen glycan isomer is a predictor of the development of hepatocellular carcinoma during nucleoside/nucleotide analog therapy

Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease

Hepatitis B surface antigen levels during natural history of chronic hepatitis B: a Chinese perspective study.

Increase of Hepatitis B Surface Antigen Loss Rate in Hepatitis B E Antigen Positive Chronic Hepatitis B Patients Treated with Nucleos (t) Ide Analogs and Pegylated Interferon Alfa-2A Sequential Therapy

Hepatitis B surface antigen (HBsAg) glycan isomer is predictive of HBsAg seroclearance in patients with chronic hepatitis B

HBsAg Levels in HBeAg-positive Chronic Hepatitis B Patients with Different Immune Conditions.

Factors associated with low hepatitis B surface antigen levels in chronic hepatitis B patients treated with nucleot(s)ide analogs

HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients

Baseline Quantitative Hepatitis B Core Antibody Titre Alone Strongly Predicts HBeAg Seroconversion Across Chronic Hepatitis B Patients Treated with Peginterferon or Nucleos(t)ide Analogues.

Correction: Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside/nucleotide analogue therapy.

Association of Hepatitis B Surface Antigen Levels With Long‐Term Complications in Chronic Hepatitis B Virus Infection: A Systematic Literature Review

Novel Biomarkers of Hepatitis B and Hepatocellular Carcinoma: Clinical Significance of HBcrAg and M2BPGi

Quantitative anti-HBc combined with quantitative HBsAg can predict HBsAg clearance in sequential combination therapy with PEG-IFN-α in NA-suppressed chronic hepatitis B patients

Kinetics and Value of Hepatitis B Core-Related Antigen in Patients with Chronic Hepatitis B Virus Infection during Antiviral Treatment

Usefulness of a Hepatitis B Surface Antigen-Based Model for the Prediction of Functional Cure in Patients with Chronic Hepatitis B Virus Infection Treated with Nucleos(t)ide Analogues: A Real-World Study

Quantitative Analyses of Intrahepatic HBV Cccdna and Serum HBsAg in 54 Patients with Chronic Hepatitis B

Serum HBV DNA plus RNA reflecting cccDNA level before and during NAs treatment in HBeAg positive CHB patients

Serum hepatitis B core-related antigen as a surrogate marker of hepatitis B e antigen seroconversion in chronic hepatitis B